Valuation : DMS

Market Cap 26.56M 30.83M 24.91M 22.74M 42.83M 2.95B 42.97M 295M 115M 1.49B 116M 113M 4.93B P/E 2026 *
34.2x
P/E 2027 * 10.3x
Enterprise Value 41.96M 48.7M 39.34M 35.92M 67.66M 4.65B 67.88M 467M 182M 2.35B 183M 179M 7.79B EV / Sales 2026 *
0.74x
EV / Sales 2027 * 0.52x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 17/07/2022
Director of Finance/CFO - 31/12/2021
Chief Tech/Sci/R&D Officer - 31/12/2018
Director TitleAgeSince
Chairman 53 17/07/2022
Director/Board Member 52 15/06/2025
Director/Board Member - 23/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 30.49M
+0.27%-0.42%-22.53%+2.50% 12.8B
-3.83%-6.27%+14.51%+4.47% 4.59B
-0.20%-5.65%-40.42%-55.80% 1.24B
+1.00%-0.63%-36.83%-36.76% 1.15B
+0.08%-0.89%+19.24%+86.69% 1.11B
-1.14%-1.20%-37.77% - 1.06B
+0.95%-3.68%+33.66%+124.70% 532M
-2.15%-1.50%+50.89% - 303M
+2.21%-4.88%-65.31%+301.00% 240M
Average -0.28%-0.14%-9.40%+60.97% 2.56B
Weighted average by Cap. -0.60%-0.13%-13.69%+8.14%

Financials

2026 *2027 *
Net sales 56.8M 65.92M 53.26M 48.61M 91.58M 6.3B 91.87M 632M 247M 3.18B 247M 242M 10.54B 65.9M 76.48M 61.79M 56.4M 106M 7.31B 107M 733M 286M 3.69B 287M 281M 12.23B
Net income 800K 928K 750K 685K 1.29M 88.73M 1.29M 8.9M 3.47M 44.79M 3.49M 3.41M 149M 2.6M 3.02M 2.44M 2.23M 4.19M 288M 4.21M 28.92M 11.28M 146M 11.33M 11.08M 483M
Net Debt 15.4M 17.87M 14.44M 13.18M 24.83M 1.71B 24.91M 171M 66.84M 862M 67.1M 65.64M 2.86B 8M 9.28M 7.5M 6.85M 12.9M 887M 12.94M 88.99M 34.72M 448M 34.86M 34.1M 1.49B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-